Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function

Clinical Immunology

Volumn 138, Issue 2, 2011, Pages 135-145

  Gaitonde, Puneet ^a   Peng, Aaron ^a   Straubinger, Robert M ^a   Bankert, Richard B ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Factor VIII; Immunogenicity; Phosphatidylserine; Regulatory T cell; Tolerance; Tolerogenic dendritic cell

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; DRUG ANTIBODY; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PHOSPHORYLCHOLINE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR VIII ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR VIII O PHOSHPOSERINE FUSION PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR VIII PHOSPHATIDYLSERINE FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FLOW CYTOMETRY; HEMOPHILIA A; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UPREGULATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD40; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; PHOSPHATIDYLSERINES; RECOMBINANT PROTEINS; UP-REGULATION;

EID: 79251564763     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.10.006     Document Type: Article

References (41)

1. Kaufman R.J., Wasley L.C., Dorner A.J. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 1988, 263(13):6352-6362.
2. Vehar G.A., et al. Structure of human factor VIII. Nature 1984, 312(5992):337-342.
3. Fay P.J. Factor VIII structure and function. Thromb. Haemost. 1993, 70(1):63-67.
4. Lollar P., et al. Factor VIII inhibitors. Adv. Exp. Med. Biol. 2001, 489:65-73.
5. Ananyeva N.M., et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul. Fibrinolysis 2004, 15(2):109-124.
6. Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang. 1999, 77(Suppl 1):17-20.
7. Pratt K.P., et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb. Haemost. 2004, 92(3):522-528.
8. Reding M.T., et al. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J. Thromb. Haemost. 2003, 1(8):1777-1784.
9. Raju R., et al. Epitopes for human CD4+ cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects. Eur. J. Immunol. 1995, 25(12):3207-3214.
10. Gilbert G.E., et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J. Biol. Chem. 2002, 277(8):6374-6381.
11. Purohit V.S., et al. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-l-serine complex. J. Biol. Chem. 2005, 280(18):17593-17600.
12. Ramani K., et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J. Pharm. Sci. 2008, 97(4):1386-1398.
13. Hoffmann P.R., et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J. Immunol. 2005, 174(3):1393-1404.
14. Duzgunes N., et al. Calcium- and magnesium-induced fusion of mixed phosphatidylserine/phosphatidylcholine vesicles: effect of ion binding. J. Membr. Biol. 1981, 59(2):115-125.
15. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 1959, 234(3):466-468.
16. Purohit V.S., et al. Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim. Biophys. Acta 2003, 1617(1-2):31-38.
17. Lutz M.B., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223(1):77-92.
18. Straubinger R.M., Papahadjopoulos D., Hong K.L. Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry 1990, 29(20):4929-4939.
19. Chirino A., Ary M., Marshall S. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 2004, 9(2):82-90.
20. Ragni M.V., et al. Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model. Exp. Hematol. 2009, 37(6):744-754.
21. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
22. Qadura M., et al. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J. Thromb. Haemost. 2008, 6(12):2095-2104.
23. Chen X., et al. Phosphatidylserine regulates the maturation of human dendritic cells. J. Immunol. 2004, 173(5):2985-2994.
24. Foged C., et al. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004, 22(15-16):1903-1913.
25. Morelli A.E., et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004, 104(10):3257-3266.
26. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134(3):392-404.
27. Gilbert G.E., Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-l-serine, a moiety of phosphatidylserine. Biochemistry 1993, 32(37):9577-9585.
28. Saenko E.L., et al. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J. Biol. Chem. 1994, 269(15):11601-11605.
29. Gilbert G.E., Arena A.A. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-l-serine. J. Biol. Chem. 1995, 270(31):18500-18505.
30. Ramani K., et al. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J. Pharm. Sci. 2008, 97(9):3753-3764.
31. Braun A., et al. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 1997, 14(10):1472-1478.
32. Ramani K., et al. Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J. Pharm. Sci. 2005, 94(6):1288-1299.
33. Purohit V.S., Middaugh C.R., Balasubramanian S.V. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J. Pharm. Sci. 2006, 95(2):358-371.
34. Fadok V.A., et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000, 405(6782):85-90.
35. Ponzin D., et al. Phosphatidylserine-induced modulation of the immune response in mice: effect of intravenous administration. Immunopharmacology 1989, 18(3):167-176.
36. Horwitz D.A., Zheng S.G., Gray J.D. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008, 29(9):429-435.
37. Zheng S.G. The critical role of TGF-beta1 in the development of induced Foxp3+ regulatory T cells. Int. J. Clin. Exp. Med. 2008, 1(3):192-202.
38. Wan Y.Y., Flavell R.A. TGF-beta and regulatory T cell in immunity and autoimmunity. J. Clin. Immunol. 2008, 28(6):647-659.
39. Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 2007, 7(8):610-621.
40. Ilarregui J.M., et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009, 10(9):981-991.
41. O'Garra A., et al. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J. Clin. Invest. 2004, 114(10):1372-1378.